These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 31990595)

  • 1. Combination and sequential treatment in women with postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Yavropoulou MP; Makras P
    Expert Opin Pharmacother; 2020 Mar; 21(4):477-490. PubMed ID: 31990595
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
    Cosman F
    Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 7. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.
    Chandran M
    Arch Endocrinol Metab; 2022 Nov; 66(5):724-738. PubMed ID: 36382762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Different Perspectives of Drug Holiday and Combination Therapies When Treating Osteoporosis].
    Oser S; Häuselmann HJ
    Praxis (Bern 1994); 2021; 110(16):975-983. PubMed ID: 34875857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
    Cosman F; Kendler DL; Langdahl BL; Leder BZ; Lewiecki EM; Miyauchi A; Rojeski M; McDermott M; Oates MK; Milmont CE; Libanati C; Ferrari S
    Osteoporos Int; 2022 Jun; 33(6):1243-1256. PubMed ID: 35165774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.
    Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Tsai JN; Leder BZ
    J Bone Miner Res; 2023 Jan; 38(1):26-34. PubMed ID: 36333954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide and denosumab combination therapy and skeletal metabolism.
    Idolazzi L; Rossini M; Viapiana O; Braga V; Fassio A; Benini C; Kunnathully V; Adami S; Gatti D
    Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
    Cosman F; Nieves JW; Dempster DW
    J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.